TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. (TSXV:ATE) is pleased to announce that it has received regulatory approval to begin its Phase I clinical trial program. Health Canada issued a No Objection Letter in response to Antibe’s Clinical Trial Application allowing the company to initiate its study entitled ‘A Double-Blind, Placebo-Controlled, Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of Single/Multiple Ascending Doses of ATB-346 Orally Administered in Healthy Male and Female Subjects.’ This approval represents a significant milestone on Antibe’s well-defined pathway for the development of ATB-346.
John Wallace, Antibe’s CSO, said, "We are excited to have received approval from Health Canada to begin studies of ATB-346 in humans. We look forward to characterizing the drug’s effects in healthy subjects in our planned Phase I clinical program, scheduled to start next week. The data from these studies will enable us to optimize the design of our proof-of-concept trials.”
About Antibe Therapeutics Inc.
Antibe Therapeutics Inc. develops safer medicines for pain and inflammation. These medicines are based on Nobel Prize-winning medical research highlighting the crucial role of gaseous mediators, chemical substances produced in the human body to regulate a range of fundamental cellular processes. The company's drug design approach involves chemically linking an existing off-patent drug to an Antibe-patented, hydrogen sulfide-releasing molecule. For medical conditions characterized by inflammation or pain, this approach can efficiently produce improved versions of existing drugs.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.